ArticleMolecular therapy : the journal of the American Society of Gene Therapy2013
Infectivity-selective oncolytic adenovirus developed by high-throughput screening of adenovirus-formatted library.
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 27 citations in OpenAlex.
- Systemic therapy with the infectivity-selective oncolytic adenovirus by targeting mesothelin.Molecular therapy. Oncology · 2025Article
- Engineered retargeting to overcome systemic delivery challenges in oncolytic adenoviral therapy.Molecular therapy. Oncology · 2025Article
- FastAd: A versatile toolkit for rapid generation of single adenoviruses or diverse adenoviral vector libraries.Molecular therapy. Methods & clinical development · 2024Article
- Interferon-expressing oncolytic adenovirus + chemoradiation inhibited pancreatic cancer growth in a hamster model.Cancer science · 2023Article
- Suppression of lysosomal acid alpha-glucosidase impacts the modulation of transcription factor EB translocation in pancreatic cancer.Cancer science · 2021Article
- Nonreplicating Adenoviral Vectors: Improving Tropism and Delivery of Cancer Gene Therapy.Cancers · 2021Review
- Intestinal Microbiota-A Promising Target for Antiviral Therapy?Frontiers in immunology · 2021Review
- Review
- Retargeting adenoviruses for therapeutic applications and vaccines.FEBS letters · 2020Review
- Gene Therapy Leaves a Vicious Cycle.Frontiers in oncology · 2019Review
- Role of Gene Therapy in Pancreatic Cancer-A Review.Cancers · 2018Review
- The Development of Oncolytic Adenovirus Therapy in the Past and Future - For the Case of Pancreatic CancerCurrent cancer drug targets · 2018Review
- CD133-targeted oncolytic adenovirus demonstrates anti-tumor effect in colorectal cancer.Oncotarget · 2017Article
- Recent advances in genetic modification of adenovirus vectors for cancer treatment.Cancer science · 2017Review
- Showing the Way: Oncolytic Adenoviruses as Chaperones of Immunostimulatory Adjuncts.Biomedicines · 2016Review
- Gene and virotherapy for hematological malignancies.International journal of hematology · 2016Review
- Oncolytic viruses: From bench to bedside with a focus on safety.Human vaccines & immunotherapeutics · 2015Review
- Adenovirus infections in immunocompetent and immunocompromised patients.Clinical microbiology reviews · 2014Review
- Development of a novel efficient method to construct an adenovirus library displaying random peptides on the fiber knob.Molecular pharmaceutics · 2014Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Adenovirus (Ad) is a potent gene-delivery vehicle and has frequently been used for designing oncolytic viruses. However, lack of selectivity on infection has hampered the achievement of sufficient in vivo efficiency. Here, we developed a novel oncolytic virus system, infectivity-selective oncolytic adenovirus (ISOAd), via direct high-throughput screening of a high-diversity targeting-ligand library in adenoviral format. Through our newly designed rescue virus system, the high-diversity Ad library carrying the random seven amino acid sequences ligand-library in the AB-loop of its fiber-knob region (5 × 10(9) diversity) was successfully generated. During the screening of this library with the cells expressing the target molecule (mesothelin, MSLN), the AB-loop sequence of the virus clones converged to one dominant sequence and a novel MSLN-targeting sequence was isolated. The virus with the isolated motif showed selective infectivity to MSLN-positive cells in vitro. In vivo, it exhibited a selective and potent antitumor effect resulted from the viral replication in MSLN-positive xenografts. The ISOAd is a novel class of oncolytic Ad, which has selectivity at the step of transduction. The selectivity at the stage of infection can open new perspectives in oncolytic Ad therapy for various diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.